Cullinan Therapeutics (NASDAQ:CGEM) Now Covered by Analysts at HC Wainwright

Key Points

• HC Wainwright has reiterated a buy rating for Cullinan Therapeutics (NASDAQ:CGEM) with a target price of $24.00, indicating a potential upside of 221.29% from the current stock price.
• Five research analysts currently rate Cullinan Therapeutics as a buy, with an average target price of $26.80, despite the company recently reporting a loss that missed consensus earnings estimates.
• Institutional investors hold 86.31% of Cullinan Therapeutics' stock, suggesting strong confidence among major financial players in the company's future prospects.

Equities research analysts at HC Wainwright assumed coverage on shares of Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) in a research report issued on Thursday, Marketbeat Ratings reports. The firm set a "buy" rating and a $24.00 price target on the stock. HC Wainwright's price target would indicate a potential upside of 193.04% from the stock's previous close. HC Wainwright also issued estimates for Cullinan Therapeutics' Q1 2026 earnings at ($1.05) EPS and Q2 2026 earnings at ($1.08) EPS.

CGEM has been the topic of a number of other research reports. Stifel Nicolaus started coverage on shares of Cullinan Therapeutics in a research report on Wednesday, June 11th. They issued a "buy" rating and a $22.00 target price on the stock. Morgan Stanley decreased their price objective on Cullinan Therapeutics from $35.00 to $28.00 and set an "overweight" rating on the stock in a report on Monday, August 18th. Finally, UBS Group dropped their target price on Cullinan Therapeutics from $30.00 to $24.00 and set a "buy" rating for the company in a report on Monday, May 12th. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $26.80.

Cullinan Therapeutics Stock Performance

NASDAQ:CGEM traded up $0.52 during mid-day trading on Thursday, reaching $8.19. The stock had a trading volume of 629,410 shares, compared to its average volume of 359,247. The stock has a market capitalization of $483.78 million, a P/E ratio of -2.54 and a beta of -0.08. The firm has a 50 day moving average price of $7.80 and a two-hundred day moving average price of $8.17. Cullinan Therapeutics has a one year low of $6.85 and a one year high of $19.89.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.24). Research analysts forecast that Cullinan Therapeutics will post -3.04 earnings per share for the current year.

Institutional Investors Weigh In On Cullinan Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Brooklyn Investment Group bought a new stake in shares of Cullinan Therapeutics in the 1st quarter worth approximately $34,000. GAMMA Investing LLC lifted its stake in Cullinan Therapeutics by 1,214.8% in the first quarter. GAMMA Investing LLC now owns 6,995 shares of the company's stock worth $53,000 after acquiring an additional 6,463 shares during the period. Tower Research Capital LLC TRC lifted its stake in Cullinan Therapeutics by 44.6% in the second quarter. Tower Research Capital LLC TRC now owns 8,182 shares of the company's stock worth $62,000 after acquiring an additional 2,523 shares during the period. Virtus ETF Advisers LLC boosted its holdings in Cullinan Therapeutics by 37.8% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,828 shares of the company's stock valued at $71,000 after acquiring an additional 1,600 shares in the last quarter. Finally, Aquatic Capital Management LLC purchased a new position in Cullinan Therapeutics during the 4th quarter valued at $77,000. Hedge funds and other institutional investors own 86.31% of the company's stock.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.